Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegaspargase + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Sigma Tau Pharmaceuticals
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
A combination chemotherapy regimen consisting of **pegaspargase** (a pegylated recombinant L-asparaginase enzyme), **gemcitabine** (a nucleoside analog antimetabolite), and **oxaliplatin** (a platinum-based cytotoxic agent). This regimen is primarily used for the treatment of **extranodal natural killer/T-cell lymphoma (ENKTL)**, particularly in advanced-stage or relapsed/refractory disease. Pegaspargase depletes asparagine needed for protein synthesis in lymphoma cells[3][7]. Gemcitabine interferes with DNA synthesis via inhibition of DNA polymerase[2][3]. Oxaliplatin induces DNA crosslinking and apoptosis[3]. Synergistic effects are observed in patients with NK/T-cell lymphoma, and all three agents show independent anti-tumor activity with combined immune modulation[3][8].
- Other names
- gemcitabine + oxaliplatin + pegaspargaseP-gemox regimen
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on pegaspargase + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegaspargase + gemcitabine + oxaliplatin.